BioTrove, Inc. Names Robert H. Ellis as President and Chief Executive Officer.

Business Editors/Health/Medical Writers

BIOWIRE2K

WOBURN, Mass.--(BUSINESS WIRE)--Oct. 20, 2003

- Colin Brenan, Ph.D., Becomes Chief Technology Officer -

BioTrove, Inc. today announced that its Chief Operating Officer, Robert H. Ellis, has been named President and Chief Executive Officer to guide the commercialization of the company's micro- and nano-scale products in molecular biology and solutions for critical bottlenecks in drug discovery. BioTrove's founding CEO, Dr. Colin Brenan becomes Chief Technology Officer and Senior Vice President, Research and Engineering Development.

According to Enrico Petrillo, M.D., General Partner at CB Health Ventures, LLC and a member of BioTrove's Board of Directors, "BioTrove has made great progress in developing its two core technologies - Living Chip(TM) and Momentum(TM). As BioTrove transitions from an R&D focus to commercializing its core technologies, Bob is an ideal person to lead the process."

BioTrove recently launched Momentum, a patented ultra high-throughput mass spectrometry technique that enables microliter-scale functional assay development and screening of intractable targets for which current technology is not an option. As companies select targets for screening, they are often forced to forgo highly promising targets because of the challenge in developing screening assays. Momentum has the potential to remove that barrier. BioTrove's other technology platform, the Living Chip(TM) successfully addresses SNP and transcription analysis by massively parallel low volume analysis of genetic, genomic, biochemical and cellular samples with parallel liquid transfer, combining the best attributes of real time PCR (data quality) and micro arrays (parallelism) on one platform with higher throughput, lower cost, better quantification and high sensitivity.

Mr. Ellis has more than 29 years of experience in analytical and biotechnology instrumentation, including 17 years of experience in the field of genetic and protein analysis. Before joining BioTrove as COO in May 2003, Ellis was at Affymetrix, where he was Executive Vice President responsible for R&D efforts for the commercialization of the company's microarray technology resulting in the development and introduction of numerous new products.

Prior to Affymetrix, Ellis was President of Genometrix and held senior executive positions at Applied Biosystems and Perkin Elmer where he was President of Applied Biosystems Japan, responsible for strategic marketing and R&D for Perkin Elmer's Applied Genetics and Nucleic Acid synthesis units. While at Applied Biosystems, he led the marketing of the world's first automated DNA sequencer that has generated over $1 billion dollars in sales since its introduction. Prior to Applied Biosystems, Mr. Ellis held a number of management positions with the Scientific Instrument Division of Hewlett Packard. He holds a B. A. from Hartwick College with a Major in Chemistry.

About BioTrove

BioTrove, Inc. is a privately held biotechnology company focused on leveraging revolutionary micro- and nano-scale engineering solutions to overcome current bottlenecks in pharmaceutical drug discovery and biotechnology. BioTrove has developped two innovative nanofluidic platforms: the Living Chip(TM) and Momentum(TM). BioTrove offers integrated nanoliter storage and ultra high throughput screening solutions for drug discovery, genetic engineering, diagnostics and materials science. For more information on BioTrove, please visit the company's Web site at www.biotrove.com.